NC 45-0095 is a synthetic nonsteroidal selective estrogen receptor modulator (SERM) which was under development by Novo Nordisk for the treatment of postmenopausal osteoporosis but was never marketed. It is a partial agonist of the estrogen receptor (IC₅₀Tooltip half-maximal inhibitory concentration (for binding inhibition) = 9.5 nM; EC₅₀Tooltip half-maximal effective concentration = 13 nM) with mixed estrogenic and antiestrogenic activity, and shows full estrogenic activity in bone and uterus (E_maxTooltip maximal efficacy (relative to moxestrol, in Ishikawa endometrial cancer cell line) = 105%). The compound is a pyrrolo indolizine derivative. Its development was discontinued by 2003.